Moderna Inc. (MRNA) News
Filter MRNA News Items
MRNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRNA News Highlights
- MRNA's 30 day story count now stands at 31.
- Over the past 24 days, the trend for MRNA's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- The most mentioned tickers in articles about MRNA are PFE, GSK and UBS.
Latest MRNA News From Around the Web
Below are the latest news stories about MODERNA INC that investors may wish to consider to help them evaluate MRNA as an investment opportunity.
Sens. Warren, Welch urge Moderna to reconsider COVID-19 shot price increaseDemocratic Sens. Elizabeth Warren (Mass.) and Peter Welch (Vt.) are asking Moderna (NASDAQ:MRNA) CEO Stephane Bancel to reconsider a price hike for COVID-19 vaccines once they become available through the commercial market. Moderna (MRNA), like rival Pfizer (PFE), has said it plans to hike the price of its COVID shot to between $110 and $... |
Is Moderna Stock A Buy As It Faces Off With Pfizer, GSK In The Massive RSV Market?Is Moderna stock a buy after unveiling promising results for its Pfizer- and GSK-rivaling RSV vaccine? Is MRNA stock a buy now? |
Could This RSV News Make Moderna a Hot Buy Again?Moderna's (NASDAQ: MRNA) business isn't in as horrible shape as bearish investors may think. The company, which has made a name for itself for its COVID-19 vaccine, has products in its pipeline that could generate significant revenue in the future beyond just COVID. One of the most promising is a vaccine candidate for respiratory syncytial virus (RSV). |
Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should KnowModerna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
Top Healthcare StocksTop healthcare stocks include Azenta for best value, Neurocrine Biosciences for fastest growth, and Signify Health for most momentum. |
Column: Moderna and Pfizer are jacking up the price of COVID vaccines. The government should stop themModerna and Pfizer have announced plans to quadruple the price of their COVID vaccines, putting them out of reach for millions. The U.S. should step in. |
Healthcare Sector Is Lagging As We Enter 2022 Earnings SeasonThe healthcare sector is perceived as defensive but in 2023 there is more investor appetite for risk based on the QQQ comeback and the XBI strength. |
An Annual Covid Booster Could Be Coming. What It Would Mean for Pfizer and Moderna.The agency appears to be aiming to make Covid-19 vaccination efforts resemble established influenza vaccination efforts. |
Moderna is hiring 2,000 employees this year. Here's where they'll be.Moderna Inc. is planning to add 2,000 employees to its 4,000-person workforce this year — and most of them will be in Massachusetts. |
12 Most Undervalued Pharma Stocks To Buy According To Hedge FundsIn this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has assigned a ‘Neutral’ outlook to the global pharmaceutical and biotech sector, indicating Fitch’s […] |